SIX narxSIX

Bitget, the leading cryptocurrency exchange and Web3 company, has unveiled an exclusive rewards program for Sonic SVM Community. Running from January 6, 2025, at 8:00 UTC, until January 11, 2025, at 8:00 UTC, this exclusive event allows users to participate in the leading gaming ecosystem on Solana to win SONIC airdrop. The Sonic SVM Community Campaign allocates $4,000 SONIC tokens. Users can win $10-$20 SONIC airdrop by completing 3 tasks: first, signing up, downloading Bitget APP and completing KYC; second, joining both Bitget Discord and BGB Holders Group; third, completing a SONIC/USDT deposit or spot trade of any amount. Rewards are limited to 300 winners and will be distributed according to the rule of first come, first served. As an innovative project, Sonic SVM is the first Solana Virtual Machine (SVM) network extension tailored specifically for games and applications. Its infrastructure supports the first Web3 TikTok App-layer to bring millions of TikTok users to Solana. The SONIC token has a carefully structured six-year distribution plan, with a total supply of 2.4 billion tokens, aiming to promote ecosystem growth and foster community engagement through various incentives. This initiative aligns with Bitget's efforts to engage its user base through interactive promotions and reward mechanisms, enhancing the investment experience for its community. The promotion of SONIC shows Bitget's commitment to supporting innovative projects in gaming, decentralized finance (DeFi), and Web3 space, as well as enabling users to explore new opportunities in a fast-paced and evolving market.$SONIC

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or or even a handful of world-changing drugs to address billion-dollar markets. The fates of these often volatile stocks are tied closely to study data and approval decisions from the U.S. Food and Drug Administration or other drug regulators.The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech industry is alive and well. Here are seven top biotech stocks with "buy" or "hold" ratings from Argus analystsVertex Pharmaceuticals specializes in developing therapies to treat cystic fibrosis, or CF. Vertex also owns the rights to 60% of the profits from sales of CRISPR Therapeutics AG's (CRSP) gene-editing therapy exa-cel, which was approved by the FDA for treating sickle cell disease in December 2023 and for treating transfusion-dependent beta thalassemia just six weeks later. Analyst Jasper Hellweg says he is bullish on Vertex's growth outlook thanks to its market-leading CF portfolio, its successful diversification outside of CF and its healthy balance sheet. Argus has a "buy" rating and $550 price target for VRTX stock, which closed at $408.32 on Jan. 7.

DOGS, a memecoin built on The Open Network (TON), has announced its development roadmap for the first half of 2025, with plans to expand into various areas, including DOGS-themed games, community bonding activities through local charity, and enhancing the use case of DOGS tokens for transactions. According to the roadmap, users will be able to use DOGS tokens, inspired by Pavel Durov's drawing of a dog, the founder of Telegram, to make online and offline shopping transactions. Options include gift cards and travel bookings, expected to be implemented by the end of this year. In addition, individuals can also register to participate in local branches of non-profit organizations, thereby promoting charity work sponsored through a charity fund worth $4.5 million, including 6 billion DOGS tokens that have not been distributed. These community initiatives clearly demonstrate real-world use cases for #memecoins#, a type of cryptocurrency often criticized for lacking practicality, value, and real purpose. DOGS Set Record Causing $TON Incident In September, the TON community announced that the DOGS token is now owned by 4.5 million different wallets, making DOGS the meme token with the highest number of hodlers in history. "53 million users have interacted with the DOGS Mini App, and 42.2 million users qualified for the airdrop token, making it the largest memecoin airdrop event in history at that time." The rapid popularity of DOGS Telegram Mini App and the influx of users participating in DOGS token mining has caused TON to encounter two block production stoppages. On August 28, 2024, TON encountered its first operational issue related to DOGS, causing severe network congestion and disrupting block production for many hours due to the demand for DOGS tokens in the airdrop event. The second incident occurred on August 29 and lasted for about six hours before the block creation process was restored. In total, TON was inactive for 12 hours within a 36-hour period due to a large number of users claiming memecoin. DYOR! $DOGS {spot}(DOGSUSDT) Follow me for more #tips#

Everyone who is here in the markets for more than six years is not surprised at all to see the current price action. And everyone knows exactly that this range is just another range to shake out weak hands. We all know it’s up only, hold.

Biotechnology stocks are among the most high-risk, high-reward stocks in the market. Many biotech companies are working to develop one or or even a handful of world-changing drugs to address billion-dollar markets. The fates of these often volatile stocks are tied closely to study data and approval decisions from the U.S. Food and Drug Administration or other drug regulators.The biotech group struggled as a whole in 2024, but analysts say the innovation that has always supported the biotech industry is alive and well. Here are seven top biotech stocks with "buy" or "hold" ratings from Argus analystsVertex Pharmaceuticals specializes in developing therapies to treat cystic fibrosis, or CF. Vertex also owns the rights to 60% of the profits from sales of CRISPR Therapeutics AG's (CRSP) gene-editing therapy exa-cel, which was approved by the FDA for treating sickle cell disease in December 2023 and for treating transfusion-dependent beta thalassemia just six weeks later. Analyst Jasper Hellweg says he is bullish on Vertex's growth outlook thanks to its market-leading CF portfolio, its successful diversification outside of CF and its healthy balance sheet. Argus has a "buy" rating and $550 price target for VRTX stock, which closed at $408.32 on Jan. 7.